CCL26 Antibody (Center) Blocking Peptide
- Known as:
- CCL26 Antibody (Center) Blocking Peptide
- Catalog number:
- BP8972c
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- CCL26 Antibody (Center) Blocking Peptide
Related genes to: CCL26 Antibody (Center) Blocking Peptide
- Gene:
- CCL26 NIH gene
- Name:
- C-C motif chemokine ligand 26
- Previous symbol:
- SCYA26
- Synonyms:
- MIP-4alpha, eotaxin-3, IMAC, MIP-4a, TSC-1
- Chromosome:
- 7q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1999-06-09
- Date modifiied:
- 2016-10-05
Related products to: CCL26 Antibody (Center) Blocking Peptide
Related articles to: CCL26 Antibody (Center) Blocking Peptide
- This study explores the role of immunological and molecular monitoring in evaluating the efficacy of skin allergy therapies. The analysis focused on Th2-associated cytokines (IL-4, IL-5, IL-13), systemic markers (IgE, CD25), and chemokines (CCL17, CCL22, CCL26) as indicators of inflammatory activity. Structural proteins of the epidermal barrier (filaggrin, claudin-1, loricrin) and regulatory microRNAs (miRNA-155, miRNA-146a) were also assessed for their contribution to skin integrity and immune regulation. The findings demonstrated that elevated IL-4 and IL-13 levels, along with an imbalance between Th2 and Treg cells, correlated with disease severity. Successful therapy was associated with decreased cytokine levels, improved expression of barrier proteins, and modulation of microRNAs, indicating restored immune balance and reduced inflammation. These results highlight the value of integrated immunological and molecular monitoring for personalised assessment of therapy efficacy and the development of combined strategies targeting both immune dysfunction and barrier restoration. - Source: PubMed
Publication date: 2026/04/15
Lisiecka Maria Zofia - Fluid protein studies in cerebrospinal fluid (CSF) and plasma have provided important insights into neurodegenerative dementias; however, there is a limited investigation of sex-related differences and cross-biofluid relationships. In Alzheimer's disease (AD), Lewy body dementia (LBD), and frontotemporal dementia (FTD), large-scale, sex-stratified analyses of paired CSF and plasma samples remain scarce. Using the multiplex and ultrasensitive capabilities of NULISAseq™ technology, this study aims to characterize sex- and disease-specific proteomic alterations associated with Central Nervous System (CNS) pathology to explore underlying mechanisms. - Source: PubMed
Publication date: 2026/05/08
Comas-Albertí AinaLladó AlbertEsteller-Gauxax DianaBorrego-Écija SergiFalgàs NeusDakterzada FaridaPérez-Millan AgnèsPuey RogerCollet-Romà TàniaGuillén NúriaMassons MiquelTort-Merino AdriàAugé Josep MariaFernandez-Villullas GuadalupeBosch BeaRuiz-García RaquelNaranjo LauraBalasa MirceaPiñol-Ripoll GerardAntonell AnnaSánchez-Valle Raquel - Platelet-rich fibrin (PRF) is extensively utilized to enhance localized tissue healing, a process that critically depends on the transient polarization of macrophages toward a pro-inflammatory phenotype. Given that PRF, like other blood clot derivatives, may intrinsically modulate macrophage behavior, we conducted a comprehensive screening assay to characterize the global macrophage response to PRF exposure. To this end, we employed two widely used monocytic cell lines-U937 (histiocytic lymphoma) and THP-1 (acute monocytic leukemia)-as models to investigate macrophage responses. Cells were exposed to lysates derived from PRF, and transcriptomic alterations were profiled using bulk RNA sequencing. Differential gene expression analysis was performed, with significance determined by an adjusted p-value threshold of <0.05. In U937-derived macrophages, gene expression profiling revealed a transcriptional signature consistent with inflammatory activation. Clustering of upregulated genes highlighted pathways associated with chemokine activity (e.g., CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL20, CCL23, CCL26, CXCL5, CXCL6, CXCL8, CXCL16, and PPBP), RAGE receptor binding (FPR1, S100A8, S100A9, and S100A12), IgG binding (FCGR1A, FCGR2A, FCGR2B, and FCGR3A), prostaglandin biosynthesis (CBR1, CD74, EDN1, FABP5, IL1B, MIF, PTGES, and PTGS1), and collagen catabolism (CTSL, FAP, MMP3, MMP7, MMP9, MMP12, MMP14, MMP19, and MRC2). In contrast, PRF exposure in THP-1 cells primarily enriched genes involved in steroid biosynthesis, suggesting a more limited or distinct response. These findings underscore U937 cells as a more responsive and appropriate bioassay for modeling inflammatory macrophage polarization in response to PRF. Moreover, the identified gene signatures recapitulate key aspects of early wound healing, providing a relevant platform for studying macrophage reactivation in chronic wound environments. - Source: PubMed
Publication date: 2026/04/22
Panahipour LaylaHuang XiaoyuZampino FrancescaMiron Richard JGruber Reinhard - Itch is the cardinal symptom contributing to patient burden in atopic dermatitis. Multiple validated itch scales are used in clinical trials, generating heterogeneous datasets. In addition, recent studies suggest an association between cytokine levels and disease severity in atopic dermatitis. This study aimed to compare the performance of different validated itch instruments and their relationship to blood cytokine profiles. Forty-nine adults with severe atopic dermatitis and severe itch were treated with 300 mg dupilumab for 16 weeks. At the initial assessment and after treatment, itch intensity and QOL were evaluated using various assessment tools. Peripheral blood samples were collected at both time points for cytokine profiling. All itch intensity scales demonstrated comparable responsiveness, irrespective of their dimension; however, the numerical rating scale consistently yielded higher scores than the visual analog scale. Macrophage-derived chemokine, CCL26, B-cell-activating factor, and IL-2R levels were significantly reduced after treatment and correlated with all (macrophage-derived chemokine and B-cell-activating factor) or subsets (CCL26 and IL-2R) of itch intensity and QOL scores. In conclusion, all validated itch intensity scales are suitable for routine clinical use; however, adhering to one instrument is recommended. The observed correlations between cytokine levels and itch scales suggest their potential as markers of disease burden in atopic dermatitis. - Source: PubMed
Publication date: 2026/04/20
Witte FelixWiegmann HenningTeitge EstherWestmeier JaanaRaker Verena KRoyeck SvenjaZeidler ClaudiaAgelopoulos KonstantinStänder Sonja - - Source: PubMed
Publication date: 2026/04/21
Yang Hyun-WooJo Yeong-InYang Hwa-EunPark Joo-HooSon Hyeong-GukMoon Jee WonPark Il-Ho